NasdaqGM - Delayed Quote USD

Principal U.S. Large-Cap Multi-Factor ETF (PLC)

30.13 -0.09 (-0.30%)
At close: December 11 at 2:33 PM EST
Loading Chart for PLC
DELL
  • Previous Close 30.22
  • Open 30.21
  • Bid --
  • Ask --
  • Day's Range 30.05 - 30.21
  • 52 Week Range 18.95 - 30.49
  • Volume 677
  • Avg. Volume 177
  • Net Assets 7.46M
  • NAV 30.20
  • PE Ratio (TTM) --
  • Yield 1.52%
  • YTD Daily Total Return 15.62%
  • Beta (5Y Monthly) 0.00
  • Expense Ratio (net) 0.15%

The investment seeks to provide investment results that closely correspond, before expenses, to the performance of the Nasdaq US Large Cap Select Leaders Core Index. Under normal circumstances, the fund invests at least 80% of its net assets, plus any borrowings for investment purposes, in equity securities of U.S. companies with large market capitalizations that compose the index at the time of purchase. The index uses a quantitative model designed to identify equity securities of companies in the Nasdaq US Large Cap Index that exhibit potential for high degrees of value, quality growth and strong momentum.

Principal Funds

Fund Family

Large Blend

Fund Category

7.46M

Net Assets

2019-07-23

Inception Date

Performance Overview: PLC

Trailing returns as of 12/16/2020. Category is Large Blend.

YTD Return

PLC
15.62%
Category
9.95%
 

1-Year Return

PLC
16.72%
Category
27.24%
 

3-Year Return

PLC
0.00%
Category
9.88%
 

Holdings: PLC

Top 10 Holdings (31.11% of Total Assets)

SymbolCompany% Assets
AAPL
Apple Inc. 6.87%
MSFT
Microsoft Corporation 5.39%
AMZN
Amazon.com, Inc. 4.30%
GOOGL
Alphabet Inc. 3.98%
FB
FB 2.50%
BRK.B
BRK.B 1.72%
XLNX
XLNX 1.66%
AMAT
Applied Materials, Inc. 1.65%
KLAC
KLA Corporation 1.55%
V
Visa Inc. 1.49%

Sector Weightings

SectorPLC
Technology   31.34%
Healthcare   14.01%
Industrials   5.53%
Utilities   1.34%
Energy   1.08%
Real Estate   0.41%

Related ETF News

Research Reports: PLC

  • Market Digest: CENT, J, LNT, AZN, BHF

    Our recent commentaries about insider sentiment, which have been based on proprietary sentiment measurements from Vickers Stock Research, have noted growing caution among corporate executives, directors and beneficial owners. We've discussed pent-up selling demand after earnings season, when insiders are broadly prohibited from trading; hedging in an environment that features a pandemic and extreme political developments in the U.S.; and insiders taking profits off the table (as they almost always do) when stock prices flirt with all-time highs.

     
  • Analyst Report: Jacobs Engineering Group Inc.

    Jacobs Engineering is a global provider of engineering, design, procurement, construction, and maintenance services as well as cyber engineering and security solutions. The firm serves industrial, commercial, and government clients in a wide variety of sectors, including water, transportation, healthcare, technology, and chemicals. Jacobs Engineering employs approximately 55,000 workers. The company generated $13.6 billion in revenue and $970 million in adjusted operating income in fiscal 2020.

    Rating
    Price Target
     
  • Analyst Report: KBR, Inc.

    KBR (formerly Kellogg, Brown & Root) is global provider of technology, integrated engineering, procurement, and construction delivery, and operations and maintenance services. The company’s business is organized into two segments: government solutions and technology solutions. KBR has customers in more than 75 countries, with operations in 40, and employs 36,000 people. The firm generated $5.6 billion in revenue and $362 million in operating income in 2019.

    Rating
    Price Target
     
  • Analyst Report: Pfizer Inc.

    Pfizer is one of the world's largest pharmaceutical firms, with annual sales over $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, neuroscience drug Lyrica, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor, representing over a fifth of total firm sales.

    Rating
    Price Target
     

Related Tickers